Moreover, elevated levels of PARP10 have been observed in up to 19% of breast tumors and 32% of ovarian tumors, as revealed in The Cancer Genome Atlas (TCGA) database (Schleicher et al., 2018). This evidence concerns the gene PARP10 and ovarian neoplasm.